Lavieri, Robert R.Dubberke, Erik R.McGill, Sarah K.Bartelt, LutherSmith, Stephanie A.Pandur, Balint K.Phillips, Sharon E.Vermillion, KristaShirey-Rice, JanaPulley, JillXu, YaominLindsell, Christopher J.Zaleski, NicoleJerome, RebeccaDoster, Ryan S.Aronoff, David M.2024-07-112024-07-112023Lavieri RR, Dubberke ER, McGill SK, et al. Walk before you run: Feasibility challenges and lessons learned from the PROCLAIM study, a multicenter randomized controlled trial of misoprostol for prevention of recurrent Clostridioides difficile during COVID-19. Anaerobe. 2023;80:102699. doi:10.1016/j.anaerobe.2023.102699https://hdl.handle.net/1805/42114We analyzed our challenging experience with a randomized controlled trial of misoprostol for prevention of recurrent C. difficile. Despite careful prescreening and thoughtful protocol modifications to facilitate enrollment, we closed the study early after enrolling just 7 participants over 3 years. We share lessons learned, noting the importance of feasibility studies, inclusion of biomarker outcomes, and dissemination of such findings to inform future research design and implementation successes.en-USPublisher PolicyBioVUC. difficileClostridioides difficileMisoprostolPheWASTrial designArticle